Eton Pharmaceuticals (ETON) Projected to Post Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Eton Pharmaceuticals to post earnings of $0.05 per share and revenue of $14.33 million for the quarter.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. On average, analysts expect Eton Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock traded down $0.37 during mid-day trading on Tuesday, hitting $16.60. 40,115 shares of the company traded hands, compared to its average volume of 180,899. The stock has a fifty day moving average price of $14.32 and a 200-day moving average price of $13.38. The stock has a market cap of $445.18 million, a price-to-earnings ratio of -75.11 and a beta of 1.22. Eton Pharmaceuticals has a one year low of $3.18 and a one year high of $18.41.

Wall Street Analysts Forecast Growth

ETON has been the subject of a number of analyst reports. HC Wainwright reissued a "buy" rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, March 19th. Finally, B. Riley reissued a "buy" rating and issued a $24.00 price target (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.